

1 **A novel whole-blood stimulation assay to detect and quantify memory T-cells in COVID-19 patients**

2 William Mouton<sup>1, 2, 3</sup>, Christelle Compagnon<sup>1, 3</sup>, Kahina Saker<sup>1</sup>, Soizic Daniel<sup>4</sup>, Xavier Lacoux<sup>4</sup>, Bruno  
3 Pozzetto<sup>5</sup>, Guy Oriol<sup>1, 3</sup>, Sophia Djebali<sup>2</sup>, Franck Berthier<sup>4</sup>, Jacqueline Marvel<sup>2</sup>, Thierry Walzer<sup>2</sup>, Karen  
4 Brengel-Pesce<sup>1, 3\*</sup>, Sophie Trouiller-Assant<sup>1, 2\*</sup> on behalf of COVID-ser study group

5 <sup>1</sup>Joint Research Unit Hospices Civils de Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital,  
6 Pierre-Bénite, France.

7 <sup>2</sup>CIRI- International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, ENS  
8 Lyon, Claude Bernard Lyon 1 University, Lyon, France.

9 <sup>3</sup>Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France.

10 <sup>4</sup>R&D – Immunoassay, bioMérieux S.A., Marcy l'Etoile, France.

11 <sup>5</sup>GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Jean Monnet University,  
12 Lyon University, Saint-Etienne, France; Laboratoire des Agents Infectieux et Hygiène, Saint-Etienne  
13 Univesity hospital, Saint-Etienne, France.

14 \*These authors share senior authorship.

15 **Corresponding author post-publication :**

16 Sophie Trouillet-Assant, PhD

17 Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux.

18 Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, France.

19 Tel: +33(0)4 72 67 87 81; Fax: +33(0)4 72 67 87 87

20 Email: [Sophie.assant@chu-lyon.fr](mailto:Sophie.assant@chu-lyon.fr)

21 **Keywords:** SARS-CoV-2 ; Immune functional assays ; T-cells response ; Immune memory

22 **Running title:** T-cells memory 6 months post COVID-19

23 **Abstract**

24 SARS-CoV-2 specific T-cells responses are essential for virus clearance. We present a novel and  
25 simple whole-blood assay allowing the detection of interferon-gamma-producing antiviral T-cells  
26 following peptide stimulation. We show that unlike neutralizing antibodies, antiviral memory T-cells  
27 persist at least 6 months in convalescent Covid-19 individuals.

28 **Introduction**

29 As our understanding of the immune response against SARS-CoV-2 improves, it becomes clear that  
30 virus-specific T-cells are key players in the control of infection and that suboptimal T-cells response  
31 likely explains Covid-19 severity in many individuals [1]. SARS-CoV-2 specific T-cells responses often  
32 target epitopes conserved in different virus clades, including variants of concern [2], and even in  
33 other seasonal human coronaviruses (HCoV) [3]. Thus, memory T-cells may be more cross-protective  
34 than antibodies against different coronavirus infections. In addition, specific SARS-CoV-2 T-cells  
35 responses have been detected in convalescent donors without antibody responses [3] suggesting  
36 that, at least in some individuals, the measurement of T-cells responses may outperform serological  
37 measurements to uncover past infections. Thus, novel immunodiagnostics that measure cellular  
38 immune response to SARS-CoV-2 are needed to assess individual immune status and evaluate  
39 emerging vaccines in a robust and standardized manner, adapted to the clinical routine.

40 For this purpose, we designed a novel semi-automated whole-blood immune functional assay (WB  
41 IFA) to detect and quantify SARS-CoV-2-specific T-cells immunity. WB assays are rapid and simple  
42 assays that preserve all interactions between circulating immune cells, which likely reflects the *in*  
43 *vivo* situation [4]. Interferon-gamma (IFN $\gamma$ ) secretion measurement following WB SARS-CoV-2  
44 peptides stimulation was used to reveal SARS-CoV-2 specific T-cells, as previously described [5].

45 Using the IFA, we monitored T-cells immunity directed against different SARS-CoV-2 proteins  
46 including nucleocapsid (NC), membrane glycoprotein (MBGP) and receptor-binding domain (RBD) in a  
47 cohort of 129 Covid-19 convalescent healthcare workers (HCWs) previously infected 6 months before

48 with SARS-CoV-2. We correlated these measurements with serological levels of antibodies (Abs)  
49 against SARS-CoV-2. We also assessed the specificity of the IFA assay for SARS-CoV-2 by performing  
50 measurements in 25 SARS-CoV-2 seronegative healthy volunteers (HV) and in 3 HCWs having  
51 experienced a previous documented infection by HCoV.

## 52 **Methods**

### 53 **Study design**

54 A prospective cohort study was conducted at the Hospices Civils de Lyon, France in HCWs with  
55 symptoms suggestive of SARS-CoV-2 infection. The clinical study was registered on ClinicalTrial.gov  
56 (NCT04341142) [6]. Written informed consent was obtained from participants and the study was  
57 approved by the national review board for biomedical research (Comité de Protection des Personnes  
58 Sud Méditerranée, ID-RCB-2020-A00932-37). Nasopharyngeal swabs collected at inclusion were  
59 tested with the BIOFIRE® Respiratory Panel (bioMérieux,). At 6 months post-infection, blood  
60 sampling was performed on 129 HCWs who were SARS-CoV-2 positive and 3 HCWs who were HKU-1  
61 or NL-63 positive. According to French procedures, a written non-opposition to the use of donated  
62 blood for research purposes was obtained from HV. The donors' personal data were anonymized  
63 before transfer to our research laboratory. We obtained approval from the local ethical committee  
64 and the French ministry of research (DC-2008-64) for handling and conservation of these samples.

### 65 **Serological investigations**

66 The presence of anti-SARS CoV-2 Ab was evaluated on serum samples using the Wantai Ab assay that  
67 measures total Abs against the RBD of the S protein and the bioMérieux Vidas® assay that measures  
68 IgG to the RBD. Positivity was established according to the threshold value recommended by each  
69 manufacturer. The neutralizing antibody (NAb) titres were determined by a virus neutralization test  
70 (VNT) using live SARS-CoV-2 virus as previously described [7].

## 71 **T-cells response after WB stimulation against SARS-CoV-2 peptides**

72 Fresh blood collected in heparanized tubes was stimulated for 22 hours at 37°C under 5% of CO<sub>2</sub> with  
73 peptide pools targeting RBD (46 peptides), MBGP (53 peptides) or NC (102 peptides) (bioMérieux,  
74 France) diluted in IFA solution (bioMérieux, France). The IFA solution was used as a negative control  
75 and a mitogen as a positive control. The peptides (15-mer) encompassed the whole protein sequence  
76 and overlapped by 5-residues. The concentration of IFN $\gamma$  in the supernatant was measured using the  
77 VIDAS automated platform (VIDAS® IFN $\gamma$  RUO, bioMérieux). The measuring range was 0.08 -8 IU/mL  
78 and IFA positivity thresholds were defined at 0.08 IU/mL. The IFN $\gamma$  response was defined as positive  
79 when the IFN $\gamma$  concentration of the test was above threshold and the negative control was below  
80 threshold or when the IFN $\gamma$  concentration of the test minus IFN $\gamma$  concentration of the negative  
81 control was above threshold. All positive controls were  $\geq$ 8 IU/mL.

## 82 **Statistical analysis**

83 For T-cells responses, comparisons were performed using non-parametric Kruskal-Wallis test and  
84 Dunn's multiple comparisons test; the overall, positive and negative percent agreements were  
85 determined between T-cells response and serological assays or VNT as previously described [8].  
86 Statistical analyses were conducted using GraphPad Prism® software (GraphPad software, La Jolla,  
87 USA) and R software. A p-value  $\leq$  0.05 was considered as statistically significant.

## 88 **Results**

89 We first monitored SARS-CoV-2 specific Abs using the Wantai total Ab kit in the three different  
90 groups of participants (HV, or convalescent HCWs with previous infection by SARS-CoV-2 or HCoV  
91 occurring 6 months before). These Abs were undetectable in the sera from the 3 HCoV positive HCWs  
92 and from the 25 HV, confirming the absence of SARS-CoV-2 previous infection. By contrast, they  
93 were detected in all 129 HCWs with documented SARS-CoV-2 infection 6 months before. Among

94 them, we observed that 82.9% (n=107) were positive for IgG anti-SARS-CoV-2 RBD detection  
95 (bioMérieux VIDAS) and that only 48.8% (n=63) had neutralizing Abs (Nabs, Supplementary Table 1).

96 We then monitored the T-cells response against MBGP, RBD and NC peptides using the IFA WB assay  
97 for the different patients' groups. A positive IFNg release was detected for 89.1% (n=115/129;  
98 median 0.51 [0.24-1.49] IU/mL), 62.4% (n=58/93; median 0.12 [0.17-0.34] IU/mL) and 97.9%  
99 (n=92/94; median 1.20 [0.60-2.48] IU/mL) of SARS-CoV-2 positive HCWs after stimulation with MBGP  
100 (Figure 1A), RBD (Figure 1B) and NC (Figure 1C) SARS-CoV-2 peptides respectively. No or very low  
101 IFNg release (<0.12 IU/mL) was detected for HV and HCoV upon stimulation with MBGP or RBD  
102 (Figure 1A et 1B). Interestingly, two of the three HCoV positive HCWs (0.45 [0.10-0.79] IU/mL), as  
103 well as 44% (n=11/25, 0.20 [0.13-0.32] IU/mL) of the HV showed a positive IFNg response upon  
104 stimulation with NC (Figure 1C), confirming that HCoV-specific T-cells cross-reacted with some of the  
105 SARS-CoV-2 NC peptides that were used [9].

106 The overall percent agreement between T-cells responses against MBGP or RBD IFA and positive IgG  
107 anti-SARS-CoV-2 RBD (BioMérieux IgG assay) was of 78.29% and 70.97% respectively. Among the 22  
108 Covid-19 convalescent HCWs with undetectable anti-SARS-CoV-2-RBD IgG, only 4 did not have MBGP-  
109 specific T-cells, which resulted in a low negative percent agreement between cellular and humoral  
110 responses (18.18% ). Moreover, among the 66 convalescent HCWs who lacked neutralizing Abs at 6  
111 months post-infection, 81.8% (n=54) had MBGP-specific T-cells (detailed in supplementary Table 1).  
112 These results suggest that, in the case of undetectable nAbs against SARS-CoV-2, a T-cells response  
113 can still be observed.

#### 114 **Concluding remarks**

115 Here, we presented a novel WB IFA assay that is highly efficient in detecting SARS-CoV-2 specific T-  
116 cells responses, especially those directed against MBGP. IFNg-release quantification following WB  
117 stimulation could thus be proposed as a suitable and rapid option for assessing the presence of a  
118 long-term specific cellular response after natural SARS-CoV-2 infection.

119 In our cohort of Covid-19 convalescent HCWs, we observed that about 90% of patients had a  
120 detectable T-cells response after SARS-CoV-2 peptide stimulation at 6 months post symptoms, in  
121 accordance with recent results [10]. Thus, our results suggest that WB IFA stimulation assays can be  
122 used to detect memory T-cells in convalescent patients, even at late phases post infection, extending  
123 previous findings by *Murugesan et al.* [5] who used a similar approach in recently-infected patients  
124 by SARS-CoV-2. Moreover, we confirmed that IFN $\gamma$  secretion was a robust read-out to assess SARS-  
125 CoV-2 memory T-cells responses over time [11]. Yet, peptides derived from distinct viral proteins  
126 showed a different capacity to trigger a T-cells response in patients. The highest positivity was  
127 observed after stimulation with NC peptides. These peptides could even induce IFN $\gamma$  secretion by  
128 HCoV-convalescent HCWs and HV T-cells, suggesting cross-reactivity between seasonal HCoV and  
129 SARS-CoV-2 and potential pre-existing immunity in HV, as previously described [9,12,13]. This also  
130 suggests that stimulation using NC peptides encompassing the whole NC protein should not be used  
131 as a specific diagnostic tool of SARS-CoV-2 immunity. By contrast, MBGP peptides seem to be more  
132 appropriate to reveal SARS-CoV-2 specific memory T-cells. We also confirmed previous findings  
133 regarding the relative short half-life of NAb and anti-SARS-CoV-2 IgGs [7]. Thus the measurement of  
134 T-cells responses may outperform serological measurements to uncover past infections.

135 We acknowledge that our study has some limitations: (i) the WB IFA assay was not able to  
136 differentiate between CD8+ and CD4+ T-cells responses, (ii) it does not determine whether memory  
137 T-cells are protective against SARS-CoV-2 re-infection and (iii) it was not yet evaluated in vaccinated  
138 subjects.

### 139 **Funding**

140 This work was supported by bioMérieux SA which provided kits for this study. This research is being  
141 supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon.

### 142 **Acknowledgments**

143 We thank all the personnel of the occupational health and medicine department of Hospices Civils de  
144 Lyon who contributed to the samples collection. We thank Karima Brahami and all members of the  
145 clinical research and innovation department for their reactivity (DRCI, Hospices Civils de Lyon). A  
146 special thanks to Virginie Pitiot and PMO team for their help in patient enrolment and clinical data  
147 collection.

148 *Potential conflicts of interest:* WM, CC, SD, XL, GO, FB and KBP, are employed in bioMérieux SA,  
149 an *in vitro* diagnostic company.

150 *No conflict of interest:* KS, BP, SD, JM, TW and STA




151

152 **Reference**

- 153 1. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* **2021**; 184:861–880.
- 154 2. Skelly DT, Harding AC, Gilbert-Jaramillo J, et al. Vaccine-induced immunity provides more  
155 robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of  
156 concern. In Review, 2021. Available at: <https://www.researchsquare.com/article/rs-226857/v1>.  
157 Accessed 8 March 2021.
- 158 3. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and  
159 COVID-19-induced T cell recognition. *Nat Immunol* **2021**; 22:74–85.
- 160 4. Albert-Vega C, Tawfik DM, Trouillet-Assant S, Vachot L, Mallet F, Textoris J. Immune Functional  
161 Assays, From Custom to Standardized Tests for Precision Medicine. *Front Immunol* **2018**;  
162 9:2367.
- 163 5. Murugesan K, Jagannathan P, Pham TD, et al. Interferon-gamma release assay for accurate  
164 detection of SARS-CoV-2 T cell response. *Clinical Infectious Diseases* **2020**; :ciaa1537.
- 165 6. Trouillet-Assant S, Albert Vega C, Bal A, et al. Assessment of serological techniques for  
166 screening patients for COVID-19 (COVID-SER): a prospective, multicentric study. *BMJ Open*  
167 **2020**; 10:e041268.
- 168 7. Bal A, Traubad M-A, Fassier J-B, et al. Six-month antibody response to SARS-CoV-2 in healthcare  
169 workers assessed by virus neutralisation and commercial assays. *Infectious Diseases (except*  
170 *HIV/AIDS)*, 2020. Available at: <http://medrxiv.org/lookup/doi/10.1101/2020.12.08.20245811>.  
171 Accessed 19 February 2021.
- 172 8. Obermeier P, Muehlhans S, Hoppe C, et al. Enabling Precision Medicine With Digital Case  
173 Classification at the Point-of-Care. *EBioMedicine* **2016**; 4:191–196.
- 174 9. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and  
175 immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Rep Med* **2021**; 2:100204.
- 176 10. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8  
177 months after infection. *Science* **2021**; 371:eabf4063.
- 178 11. Pérez-Cabezas B, Ribeiro R, Costa I, et al. IL-2 and IFN- $\gamma$  are biomarkers of SARS-CoV-2 specific  
179 cellular response in whole blood stimulation assays. *Infectious Diseases (except HIV/AIDS)*,  
180 2021. Available at: <http://medrxiv.org/lookup/doi/10.1101/2021.01.04.20248897>. Accessed 18  
181 February 2021.
- 182 12. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus  
183 in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **2020**; 181:1489-1501.e15.
- 184 13. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in  
185 unexposed humans. *Science* **2020**; 370:89–94.

186



**A. MBGP peptides stimulation****B. RBD peptides stimulation****C. NC peptides stimulation**

## Figure legend

**Figure 1: IFN $\gamma$  release after *in vitro* WB stimulation using SARS-CoV-2 peptide pools.** IFN $\gamma$  levels in WB samples from 129 SARS-CoV-2 convalescent HCWs (dot), 3 HCoV convalescent HCWs (square) and 25 controls (HV) (triangle). IFN $\gamma$  secretion was measured after a 22-hour stimulation using **(A)** MBGP peptides, **(B)** RBD peptides and **(C)** NC peptides. Statistical differences were inferred using non-parametric Kruskal-Wallis test and Dunn's multiple comparisons test.

Abbreviations: HCoV: seasonal human coronaviruses; HCWs: healthcare workers; HV: healthy volunteers; IU: international unit; MBGP: membrane glycoprotein; NC: nucleocapsid; RBD: receptor binding domain.